Drug Profile
Donidalorsen - Ionis Pharmaceuticals
Alternative Names: Donidalorsen sodium; IONIS-PKK-L Rx; ISIS 721744Latest Information Update: 01 Apr 2024
Price :
$50
*
At a glance
- Originator Ionis Pharmaceuticals
- Class Anti-inflammatories; Antisense oligonucleotides; Vascular disorder therapies
- Mechanism of Action Plasma kallikrein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hereditary angioedema
- Phase II COVID 2019 infections
Most Recent Events
- 01 Apr 2024 Updated efficacy and adverse event data from a phase II trial in Hereditary angioedema presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2024)
- 23 Feb 2024 Efficacy and adverse event data from the phase II extension trial in Hereditary angioedema presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology 2024 (AAAAI-2024)
- 19 Feb 2024 Donidalorsen - Ionis Pharmaceuticals receives Orphan Drug status for Hereditary angioedema in European Union